

Prescribing Clinical Network

Policy Statement	Co-proxamol
Policy Number	PCN 306-2018
Date of Issue	January - 2018
Review Date:	January - 2021 (Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)

Recommendations:

The Prescribing Clinical Network does not recommend the use of co-proxamol.

Co-proxamol will be considered **BLACK** on the traffic light system. Prescribers should:

- NOT initiate co-proxamol for any new patient AND
- Switch patients taking co-proxamol to an alternative pain medication, in line with NHS England guidance.

Key Considerations:

 NHS England guidance 'Items which should not routinely be prescribe in primary care: Guidance for CCGs' - https://www.england.nhs.uk/wp-content/uploads/2017/11/items-which-should-not-be-routinely-precscribed-in-pc-ccg-guidance.pdf

Co-proxamol was fully withdrawn from the UK market in 2007 due to safety concerns. All use in the UK is now on an unlicensed basis. Since the withdrawal further safety concerns have been raised which have resulted co-proxamol being withdrawn in other countries.

Date taken to Prescribing Clinical Network	10 th January 2018
Agreed by PCN members	22 nd January 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG